---
title: "Bristol-Myers Squibb Company (BMY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BMY.US.md"
symbol: "BMY.US"
name: "Bristol-Myers Squibb Company"
industry: "Pharmaceuticals"
datetime: "2026-05-19T14:08:33.217Z"
locales:
  - [en](https://longbridge.com/en/quote/BMY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BMY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BMY.US.md)
---

# Bristol-Myers Squibb Company (BMY.US)

## Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.bms.com](https://www.bms.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 39 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.78% |  |
| Net Profit YoY | 34.25% |  |
| P/B Ratio | 5.83 |  |
| Dividend Ratio | 4.36% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 117031103165.57 |  |
| Revenue | 48482000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 38.84% | A |
| Profit Margin | 15.01% | A |
| Gross Margin | 70.34% | A |
| Revenue YoY | 1.78% | C |
| Net Profit YoY | 34.25% | B |
| Total Assets YoY | -6.44% | D |
| Net Assets YoY | 15.21% | B |
| Cash Flow Margin | 182.90% | B |
| OCF YoY | 1.78% | C |
| Turnover | 0.54 | C |
| Gearing Ratio | 76.75% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Bristol-Myers Squibb Company",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "34.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.83",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.36%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "117031103165.57",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "48482000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "38.84%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "15.01%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "70.34%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.78%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "34.25%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.44%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "15.21%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "182.90%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.78%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "76.75%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 16.09 | 30/190 | 18.44 | 17.67 | 17.02 |
| PB | 5.83 | 156/190 | 6.41 | 5.64 | 5.36 |
| PS (TTM) | 2.41 | 67/190 | 2.46 | 2.08 | 1.98 |
| Dividend Yield | 4.36% | 6/190 | 5.31% | 5.04% | 4.29% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **30**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 20% |
| Overweight | 4 | 13% |
| Hold | 18 | 60% |
| Sell | 1 | 3% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 57.87 |
| Highest Target | 75.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BMY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BMY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BMY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BMY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**